Novo Nordisk halts two more trials for experimental heart disease drug

Novo Nordisk stopped two more trials for its experimental heart disease medicine, further damaging the drug's prospects. A separate report noted semaglutide showed no new safety concerns in children.

Detected & updated continuously · Source: Nebula